PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Judge Arrested for Child Porn Headed Drag Queen Story Hour Club

Show Me

Amazon Won’t Sell Books Framing LGBTQ+ Identities as Mental Illnesses

Show Me

Author Says Amazon Used Lie to Justify Censoring His Book

Show Me

Mississippi governor signs bill to ban transgender athletes from women’s sports

Show Me

No Prison For Transgender Neo-Nazi After Threatening Black, Jewish Journalists

Show Me

Arkansas governor signs transgender sports ban into law

Show Me

Transgender actor Elliot Page knew he ‘wanted to be a boy’ at age NINE

Show Me

Mississippi Becomes First State to Ban Transgender Students from Women’s Sports

Show Me

Trans Model Leyna Bloom Lands Spot In 2021 Sports Illustrated Swimsuit Issue

Show Me

Rachel Levine Becomes First Openly Trans Person to Win Senate Confirmation

Show Me

Transgender teen Stella Keating receives viral praise after testifying before Congress on Equality Act

Show Me

Women’s rights groups back transgender athletes competing in female sporting events

Show Me

BREAKING: Arkansas House Overrides Governor’s Veto Of Bill Banning Trans Puberty Blockers For Children

Show Me

Florida Legislature Approves Transgender Athlete Sports Ban

Show Me

Richard Dawkins Punished for Inviting us to Think

Show Me

‘Men Don’t Belong In My Sport’: Female Wrestler Calls Out Biden’s Trans Athlete Agenda

Show Me

Biden Withdraws Trump Transgender Proposal for Homeless Shelters

Show Me

Judge Thapar Asked Then If The University Would Force A Jewish Professor To Honor A Student’s Request To Be Addressed As “My Fuhrer.” | “Professor Can’t Be Punished For Not Using Transgender Student’s Pronouns, Appeals Court Rules”

Show Me

NCAA ‘Unequivocally Supports’ Transgender Biological Male Participation in College Women’s Sports

Show Me

SHOW NOTES: Thanks, Trevor Noah! Erasing Women’s Achievements One Puberty Blocker at a Time!

Show Me

261 Transgender Prisoners Request Transfer Under California Law; 255 to Women’s Prison

Show Me

Richard Dawkins is stripped of his Humanist Of The Year award

Show Me

Musician Ezra Furman announces she’s a transgender woman

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded July 3, 2021 | Video: 48 Minutes 55 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded July 3, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Freedom Tour Charlotte: Devin Nunes and Rumble CEO Chris Pavlovski

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 2, 2021 | Video: 48 Minutes 23 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 2, 2021 | Video: 48 Minutes 34 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 2, 2021 | Video: 48 Minutes 58 Seconds

Show Me

PART 1: Why Mike Lindell WON’T Back Down

Show Me

PART 2: See No, Hear No, Speak No Election Fraud – Fighting the Good Fight Against Censorship

Show Me

PART 3: Mike Lindell Announces His Cyber Symposium, He is Laying it ALL Out There

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 1, 2021 | Video: 48 Minutes 23 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 1, 2021 | Video: 48 Minutes 10 Seconds

Show Me

China leader Xi Jinping those who attempt to ‘bully’ will face ‘bloodshed,’ at Communist Party event

Show Me

Britney Spears and the Age-Old History of Men Policing Women’s Trauma

Show Me

Trump CFO Surrenders to Manhattan DA This Morning On Garbage Charges As Obama/Biden Try to Destroy the Trump Organization

Show Me

Deaths From Vaccine Top 6K As FDA Issues Warning After Spike In Cases Of Fatal Heart Inflammation

Show Me

Bannon’s War Room | Evening Edition | Recorded July 1, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded June 30, 2021 | Video: 48 Minutes 45 Seconds

Show Me